Tailwinds’ Take: CDXC stock has been weak with a combination of lack of news and forecasted sales not picking up until Q3 weighing on the stock. Summer doldrums will likely be your buying opportunity here.
IRVINE, Calif., May 29, 2018 (GLOBE NEWSWIRE) — ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age, announced today that it will feature its novel form of vitamin B3, TRU NIAGEN® (Booth #405), at the American Society for Nutrition’s Annual Meeting, a gathering of 2500 scientists, healthcare practitioners, researchers and policy makers, June 9-12 in Boston, MA.
Members of the TRU NIAGEN team will be on site to discuss the scientific evidence behind the efficacy of the novel B3, as well as a recently published clinical trial supporting its benefit in humans. Visitors will also receive a complimentary supply of TRU NIAGEN at the booth—come early as quantities are limited.
Charles Brenner, PhD, Roy J. Carver Chair and Head of Biochemistry at the University of Iowa, and Chief Scientific Adviser of ChromaDex, who discovered the vitamin activity of nicotinamide riboside (NR), will be available to meet with attendees at the TRU NIAGEN booth on Sunday, June 10 from 12-2pm. Brenner continues to conduct groundbreaking research on NR, and will share his expertise in his talk entitled “Boosting Metabolism with Nicotinamide Riboside: Full Circle From Milk.”
For additional information on the science supporting TRU NIAGEN visit www.truniagen.com.
About TRU NIAGEN®:
TRU NIAGEN® is a branded dietary supplement brought to market by key nicotinamide riboside innovator and patent holder, ChromaDex. NIAGEN® nicotinamide riboside (NR), also supplied by ChromaDex, is the sole active ingredient in TRU NIAGEN®. Multiple clinical trials demonstrate NIAGEN® is proven to boost NAD (nicotinamide adenine dinucleotide) levels, which decline with age. Only NIAGEN® has twice been successfully reviewed under FDA’s new dietary ingredient (“NDI”) notification program, and has also been successfully notified to the FDA as generally recognized as safe (“GRAS”).
ChromaDex Corp. is an integrated, global nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to uncover the full potential of NAD and identify and develop novel, science-based ingredients. Its flagship ingredient, NIAGEN® nicotinamide riboside, sold directly to consumers as TRU NIAGEN®, is backed with clinical and scientific research, as well as extensive IP protection. TRU NIAGEN is helping the world AGE BETTER®. To learn more about ChromaDex, please visit www.ChromaDex.com.
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, including statements related to results of the NIAGEN® studies and their significance. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as “expects”, “anticipates”, “intends”, “estimates”, “plans”, “potential”, “possible”, “probable”, “believes”, “seeks”, “may”, “will”, “should”, “could” or the negative of such terms or other similar expressions. More detailed information about ChromaDex and the risk factors that may affect the realization of forward-looking statements is set forth in ChromaDex’s Annual Report on Form 10-K for the fiscal year ended December 30, 2017, ChromaDex’s Quarterly Reports on Form 10-Q and other filings submitted by ChromaDex to the SEC, copies of which may be obtained from the SEC’s website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and ChromaDex undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof. ChromaDex provided research materials and a portion of the grant funding as a collaborator for the study.
ChromaDex Media Contact:
Alex Worsham, Director of Strategic Partnerships
ChromaDex Investor Relations Contact:
Andrew Johnson, Director of Investor Relations